Advertisement

European Journal of Clinical Pharmacology

, Volume 71, Issue 9, pp 1129–1138 | Cite as

Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990–2012

  • Thomas StammschulteEmail author
  • Wolf-Dieter Ludwig
  • Bernd Mühlbauer
  • Elisabeth Bronder
  • Ursula Gundert-Remy
Pharmacoepidemiology and Prescription

Abstract

Purpose

In 1986, the risk of agranulocytosis prompted German authorities to restrict the indications for metamizole use. After an initial decline, prescriptions increased from <20 million defined daily doses in 1990 to >140 million in 2012. Concurrently, spontaneous reports of agranulocytosis increased from about 10 in 1990 to >50 in 2012. In this study, reports were analyzed to identify targets for risk minimization measures.

Methods

Reports of suspected metamizole-induced agranulocytosis (neutrophils <0.5 × 109 cells/l) between 1990 and 2012 were identified in the German spontaneous reporting database. Cases for which original reporting documents were available were eligible for analysis. Patient characteristics, indication, clinical course, and outcome were assessed.

Results

One hundred sixty-one reports were analyzed. The mean age of the patients was 56.8 years (11–93) and 64.6 % were female. Off-label use was identified in about 25 % of cases. Neutrophils fell below 100/μl in 63 and intercurrent infections developed in 109 cases. Thirty-eight patients (23.6 %) died. In two thirds of the cases, agranulocytosis occurred within 6 weeks of permanent or intermittent metamizole treatment, in 30.5 % within 7 days, including 18 cases of immediate onset after the first or second administration.

Conclusion

The reported cases show severe clinical courses and are, to some extent, a result of off-label use. Due to the absence of individual risk factors and presence of variable onset patterns, risk minimization measures should focus on restricting use to defined clinical situations and providing concise risk information for patients and healthcare professionals.

Keywords

Metamizole Dipyrone Agranulocytosis Spontaneous reports Germany 

Notes

Acknowledgments

The authors would like to thank Siobhan O’Leary and Henry Pachl for the editing assistance.

Author contribution

Performed research: TS, EB, UGR. Analyzed data: TS, EB, UGR. Wrote manuscript: TS, WDL, BM, EB, UGR.

For this type of study, formal consent is not required.

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

228_2015_1895_MOESM1_ESM.tif (1.1 mb)
ESM 1 Indications for metamizole in 161 spontaneous reports of suspected metamizole-induced agranulocytosis (TIFF 1.14 mb)

References

  1. 1.
    Curtis BR (2014) Drug-induced immune neutropenia/agranulocytosis. Immunohematology 30:95–101PubMedGoogle Scholar
  2. 2.
    Theophile H, Begaud B, Martin K et al (2004) Incidence of agranulocytosis in Southwest France. Eur J Epidemiol 19:563–565PubMedCrossRefGoogle Scholar
  3. 3.
    van der Klauw MM, Stricker BH, Herings RM et al (1993) A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol 35:400–408PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Huber M, Andersohn F, Bronder E et al (2014) Drug-induced agranulocytosis in the Berlin case-control surveillance study. Eur J Clin Pharmacol 70:339–345PubMedCrossRefGoogle Scholar
  5. 5.
    Tesfa D, Keisu M, Palmblad J (2009) Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 84:428–434PubMedCrossRefGoogle Scholar
  6. 6.
    Uetrecht JP (1996) Reactive metabolites and agranulocytosis. Eur J Haematol Suppl 60:83–88PubMedGoogle Scholar
  7. 7.
    Hargis JB, La Russa VF, Redmond J et al (1989) Agranulocytosis associated with “Mexican aspirin” (dipyrone): evidence for an autoimmune mechanism affecting multipotential hematopoietic progenitors. Am J Hematol 31:213–215PubMedCrossRefGoogle Scholar
  8. 8.
    Salama A, Schutz B, Kiefel V et al (1989) Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies. Br J Haematol 72:127–132PubMedCrossRefGoogle Scholar
  9. 9.
    FDA: List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness (Federal Register: October 8, 1998 (Volume 63, Number 195)): http://www.fda.gov/ohrms/dockets/98fr/100898b.txt. Accessed 6 Jul 2013.
  10. 10.
    Bhaumik S (2013) India's health ministry bans pioglitazone, metamizole, and flupentixol-melitracen. BMJ 347:f4366PubMedCrossRefGoogle Scholar
  11. 11.
    Arzneimittelkommission der deutschen Ärzteschaft: Bundesgesundheitsamt schränkt Anwendungsgebiet von Metamizol-haltigen Monopräparaten ein. Dtsch Arztebl 1986;83:3267.Google Scholar
  12. 12.
    Schwabe U, Paffrath D (Hrsg.): Arzneiverordnungs-Report (German Drug Report) 2013. Berlin, Heidelberg: Springer Medizin Verlag; 2013Google Scholar
  13. 13.
    Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 60:821–829PubMedCrossRefGoogle Scholar
  14. 14.
    Huber M, Andersohn F, Sarganas G et al (2014) Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol 71:219–227PubMedCrossRefGoogle Scholar
  15. 15.
    Blaser LS, Tramonti A, Egger P et al (2015) Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. Eur J Clin Pharmacol 71:209–217PubMedCrossRefGoogle Scholar
  16. 16.
    (Muster-)Berufsordnung für die in Deutschland tätigen Ärztinnen und Ärzte [(Model) Professional Code for Physicians in Germany]: http://www.bundesaerztekammer.de/downloads/MBO_08_20112.pdf. Kiel, 114th German Medical Assembly 2011. Accessed 6 June 2014.
  17. 17.
    Development and rational use of standardised MedDRA Queries (SMQs). Geneva: Council for International Organizations of Medical Sciences (CIOMS); 2004.Google Scholar
  18. 18.
    World Health Organization: The use of the WHO-UMC system for standardised case causality assessment: http://who-umc.org/Graphics/24734.pdf. Accessed 10 June 2015.
  19. 19.
    Stammschulte T, Pachl H, Gundert-Remy U (2013) Do older patients take more drugs and are they at higher risk of adverse drug reactions? What do our spontaneous reports say? Drug Saf 36:813Google Scholar
  20. 20.
    Hamerschlak N, Maluf E, Biasi CA et al (2008) Incidence and risk factors for agranulocytosis in Latin American countries—the Latin Study: a multicenter study. Eur J Clin Pharmacol 64:921–929PubMedCrossRefGoogle Scholar
  21. 21.
    Ibanez L, Vidal X, Ballarin E, Laporte JR (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165:869–874PubMedCrossRefGoogle Scholar
  22. 22.
    Shapiro S, Issaragrisil S, Kaufman DW et al (1999) Agranulocytosis in Bangkok, Thailand: a predominantly drug-induced disease with an unusually low incidence. Aplastic Anemia Study Group. Am J Trop Med Hyg 60:573–577PubMedGoogle Scholar
  23. 23.
    Hedenmalm K, Spigset O (2002) Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 58:265–274PubMedCrossRefGoogle Scholar
  24. 24.
    Andres E, Maloisel F, Kurtz JE et al (2002) Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med 13:324–328PubMedCrossRefGoogle Scholar
  25. 25.
    Andersohn F, Konzen C, Garbe E (2007) Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146:657–665PubMedCrossRefGoogle Scholar
  26. 26.
    Gualde N, Malinvaud G (1982) In vitro generation of cytotoxic lymphocytes during noramidopyrine-induced agranulocytosis. Clin Immunol Immunopathol 24:220–226PubMedCrossRefGoogle Scholar
  27. 27.
    Sanofi-Aventis Deutschland GmbH: Fachinformation “Novalgin®”. Stand: Januar 2011.Google Scholar
  28. 28.
    Arzneimittelkommission der deutschen Ärzteschaft: “Aus der UAW-Datenbank”: Agranulozytose nach Metamizol - sehr selten, aber häufiger als gedacht. Dtsch Arztebl 2011;108:A 1758-1759.Google Scholar
  29. 29.
    BfArM: Metamizol (Novalgin, Berlosin, Novaminsulfon, etc.): BfArM weist auf richtige Indikationsstellung und Beachtung von Vorsichtsmaßnahmen und Warnhinweisen hin (28.05.2009): http://www.bfarm.de/DE/Pharmakovigilanz/risikoinfo/Archiv/2009/RI-metamizol.html. Accessed 6 Jul 2013.

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Thomas Stammschulte
    • 1
    Email author
  • Wolf-Dieter Ludwig
    • 1
    • 2
  • Bernd Mühlbauer
    • 1
    • 3
  • Elisabeth Bronder
    • 1
  • Ursula Gundert-Remy
    • 1
  1. 1.Drug Commission of the German Medical Association (DCGMA)BerlinGermany
  2. 2.Department of Hematology, Oncology, and Tumor ImmunologyHELIOS Klinikum Berlin-BuchBerlinGermany
  3. 3.Department of PharmacologyKlinikum Bremen-Mitte gGmbHBremenGermany

Personalised recommendations